Lexicon Pharmaceuticals Inc (LXRX)

15.42
0.33 2.10
NASDAQ : Health Care
Prev Close 15.75
Open 15.75
Day Low/High 15.15 / 15.75
52 Wk Low/High 7.65 / 15.84
Volume 211.27K
Avg Volume 727.80K
Exchange NASDAQ
Shares Outstanding 104.04M
Market Cap 1.67B
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Lexicon Announces Publication Of TELESTAR Study Results For Telotristat Ethyl In The Journal Of Clinical Oncology

Lexicon Announces Publication Of TELESTAR Study Results For Telotristat Ethyl In The Journal Of Clinical Oncology

Results from Pivotal Phase 3 Clinical Study of Telotristat Ethyl Show Clinical Benefit in Patients with Carcinoid Syndrome

Lexicon Reports Positive Top-Line Results In Phase 2 Dose-Ranging Study For Sotagliflozin In Patients With Type 1 Diabetes

Lexicon Reports Positive Top-Line Results In Phase 2 Dose-Ranging Study For Sotagliflozin In Patients With Type 1 Diabetes

Results Support Phase 3 Dose Selection and Differentiated Dual SGLT1/SGLT2 Mechanism

Lexicon To Report Third Quarter 2016 Financial Results On November 1, 2016

Lexicon To Report Third Quarter 2016 Financial Results On November 1, 2016

Conference Call and Webcast to Follow

Short Interest In Lexicon Pharmaceuticals Moves 16% Higher

Short Interest In Lexicon Pharmaceuticals Moves 16% Higher

The most recent short interest data has been released for the 09/30/2016 settlement date, which shows a 2,011,299 share increase in total short interest for Lexicon Pharmaceuticals, Inc. , to 14,608,790, an increase of 15.97% since 09/15/2016.

Telecast Data Presented At The 2016 North American Neuroendocrine Tumor Society Annual Symposium

Telecast Data Presented At The 2016 North American Neuroendocrine Tumor Society Annual Symposium

First Presentation at a Scientific Meeting of Data from Companion Phase 3 Trial Designed to Assess Safety of Telotristat Ethyl for Carcinoid Syndrome

FDA Extends PDUFA Date For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome

FDA Extends PDUFA Date For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome

PDUFA Goal Date Extended to February 28, 2017

Lexicon Reports Positive Top-Line Results In Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes

Lexicon Reports Positive Top-Line Results In Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes

First Successful Phase 3 Trial of an Oral Anti-diabetic for Type 1 Diabetes

Lexicon To Report Second Quarter 2016 Financial Results On August 4, 2016

Lexicon To Report Second Quarter 2016 Financial Results On August 4, 2016

Conference Call and Webcast to Follow

First Week Of LXRX August 19th Options Trading

First Week Of LXRX August 19th Options Trading

Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the August 19th expiration.

7 Stocks Spiking on Big Volume

7 Stocks Spiking on Big Volume

Here's a technical look at how to trade seven stocks rising on unusual volume.

Lexicon To Report First Quarter 2016 Financial Results On May 3, 2016

Lexicon To Report First Quarter 2016 Financial Results On May 3, 2016

Conference Call and Webcast to Follow

Lexicon Pharmaceuticals (LXRX) Weak On High Volume Today

Lexicon Pharmaceuticals (LXRX) Weak On High Volume Today

Trade-Ideas LLC identified Lexicon Pharmaceuticals (LXRX) as a weak on high relative volume candidate